Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Daré Bioscience, Inc. (DARE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.5700+0.0200 (+1.29%)
At close: 4:00PM EDT
1.5600 -0.01 (-0.64%)
After hours: 07:55PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close1.5500
Open1.5800
Bid1.5500 x 4000
Ask1.5800 x 1800
Day's Range1.5400 - 1.5800
52 Week Range0.9450 - 3.8500
Volume1,019,481
Avg. Volume3,445,135
Market Cap110.72M
Beta (5Y Monthly)1.50
PE Ratio (TTM)N/A
EPS (TTM)-0.7890
Earnings DateNov 10, 2021 - Nov 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.40
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for DARE

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Dare Bioscience, Inc.
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion. Pfizer also spends a leading amount on research and development, close to $8 billion annually. While Pfizer historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
    Rating
    Fair Value
    Economic Moat
    5 days agoMorningstar
View more
  • GlobeNewswire

    Daré Bioscience to Participate in Panel Discussion at DTC Perspectives’ Xpectives.Health Summit, October 12-14, 2021

    An interactive conversation regarding the importance of industry and investor commitment to women’s health innovationSAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced its participation in DTC Perspectives’ Xpectives.Health Summit being held in Boston, MA from October 12 – 14, 2021, at The Westin Copley Place. “I’m excited to be part of an esteemed panel of women to discuss the commitment and participation of

  • GlobeNewswire

    Daré Bioscience Announces NIH Grant Award to Support Development of DARE-LARC1

    DARE-LARC1 Aims to Combine the Benefits of Long-acting Reversible Contraception with User-Controlled Flexibility to Pause or Resume Contraception as DesiredSAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced a Notice of Award of a grant from the Eunice Kennedy Shriver National Institute Of Child Health & Human Development (NICHD), a division of the National Institutes of Health (NIH), for $309,614. This grant w

  • Zacks

    Dare (DARE) Begins Study to Treat Vulvar and Vaginal Atrophy

    Dare Bioscience (DARE) starts a phase I/II study to evaluate DARE-VVA1 to treat moderate to severe vulvar and vaginal atrophy.

Advertisement
Advertisement